What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Disease
Nicholas Moore focuses on Internal medicine, Confidence interval, Pharmacology, Pharmacovigilance and Odds ratio.
Nicholas Moore has included themes like Cardiology, Ibuprofen and Polysomnography in his Internal medicine study.
His research integrates issues of Epidemiology, Surgery, Case-control study, Meta-analysis and Placebo in his study of Confidence interval.
Nicholas Moore has researched Pharmacology in several fields, including Alternative medicine and Clinical trial.
His Pharmacovigilance research incorporates elements of Dabigatran, Marketing, Concomitant and Mortality rate.
Nicholas Moore interconnects Rivaroxaban, Occupational safety and health and Adverse Event Reporting System in the investigation of issues within Odds ratio.
His most cited work include:
- The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. (170 citations)
- The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. (170 citations)
- Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. (139 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Cohort study, Pharmacology, Pharmacoepidemiology and Cohort.
He works mostly in the field of Internal medicine, limiting it down to topics relating to Surgery and, in certain cases, Clinical trial, as a part of the same area of interest.
His studies deal with areas such as Dabigatran, Rivaroxaban, Atrial fibrillation and Hazard ratio as well as Cohort study.
His research in Drug and Adverse effect are components of Pharmacology.
His Pharmacoepidemiology study frequently draws connections between related disciplines such as Pharmacovigilance.
His work in Confidence interval is not limited to one particular discipline; it also encompasses Odds ratio.
He most often published in these fields:
- Internal medicine (51.03%)
- Cohort study (16.03%)
- Pharmacology (15.69%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (51.03%)
- Cohort study (16.03%)
- Pharmacoepidemiology (12.41%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Cohort study, Pharmacoepidemiology, Cohort and Confidence interval.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Oncology.
His Cohort study research integrates issues from Rivaroxaban, Surgery, Emergency medicine, Atrial fibrillation and Pediatrics.
His Pharmacoepidemiology research focuses on subjects like Drug, which are linked to Observational study.
His Cohort study incorporates themes from Statin and Colorectal cancer.
His research on Confidence interval often connects related topics like Odds ratio.
Between 2015 and 2021, his most popular works were:
- The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. (170 citations)
- The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. (170 citations)
- Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients (116 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
His primary areas of study are Internal medicine, Cohort study, Confidence interval, Pharmacoepidemiology and Surgery.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Diclofenac.
His study in Cohort study is interdisciplinary in nature, drawing from both Acute coronary syndrome, FOLFIRI, Hazard ratio, Colorectal cancer and Cohort.
The study incorporates disciplines such as Odds ratio, Risperidone and Sudden cardiac death in addition to Confidence interval.
His Pharmacoepidemiology research is multidisciplinary, incorporating perspectives in Heart failure, Medical diagnosis, Intensive care medicine, Medical emergency and Apixaban.
The Surgery study combines topics in areas such as Relative risk and Cetuximab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
